BioSpace News Archive

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share.

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result in gross proceeds of approximately $75.6 million, before underwriting discounts and commissions.

The rising need for organ transplants has been eliciting increasing demand for biomedical refrigerators and freezers across North American nations of late.

Several recent developments across the dental industry such as the rising number of clinical trials have been acting as stimulants for the North America dental implants market forecast.

The growing inclination toward the adoption of personalized medicine is likely to ascertain that the demand for in-vitro diagnostics in North America remains high.

The North America self-monitoring blood glucose devices market is poised for remarkable expansion due to the increasing adoption of unhealthy and detrimental dietary habits, alongside the physically inactive lifestyles resulting in the growth of obese populace.

Abram Scientific today announced it has secured a $2.9 million US Army Grant in support of the company’s effort to address the COVID-19 pandemic. This grant supports the clinical development of the CoagCare System to screen for COVID-19 related blood clotting disorders or coagulopathies in patients. The CoagCare System is intended

North American Partners in Anesthesia is growing its New England regional service area with a new clinical partnership at Lawrence General Hospital.

ARUP Laboratories, a major provider of COVID-19 molecular diagnostic testing in Utah and nationwide, announced that it is sequencing variants of SARS-CoV-2 in specimens positive for COVID-19 to enable detection of the more contagious “United Kingdom variant” of the virus.

The Epilepsy Foundation launched the 2.6-million-mile challenge to encourage people across the country to walk 2.6 million miles and raise $1.75M collectively for the 1 in 26 people living with epilepsy.